LGND Q4 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M-54.7% YoY

Gross Profit

$25M92.8% margin

Operating Income

-$10M-37.7% margin

Net Income

-$7M-27.3% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+8.8%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$10M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$728M

Stockholders' Equity

$767M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$60M	-54.7%
Gross Profit	$25M	$57M	-55.7%
Operating Income	-$10M	$33M	-130.7%
Net Income	-$7M	-$42M	+82.7%